Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Disc. 2017;16:273–84. https://doi.org/10.1038/nrd.2016.253.

Article  CAS  Google Scholar 

Banito A, Li X, Laporte AN, Roe JS, Sanchez-Vega F, Huang CH, Dancsok AR, Hatzi K, Chen CC, Tschaharganeh DF, Chandwani R, Tasdemir N, Jones KB, Capecchi MR, Vakoc CR, Schultz N, Ladanyi M, Nielsen TO, Lowe SW. The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;33:527-41.e8. https://doi.org/10.1016/j.ccell.2018.01.018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benabdallah NS, Dalal V, Scott RW, Marcous F, Sotiriou A, Kommoss FKF, Pejkovska A, Gaspar L, Wagner L, Sánchez-Rivera FJ, Ta M, Thornton S, Nielsen TO, Underhill TM, Banito A. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability. Nat Struct Mol Biol. 2023;30:1640–52. https://doi.org/10.1038/s41594-023-01096-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng Y, Shen Z, Gao Y, Chen F, Xu H, Mo Q, Chu X, Peng CL, McKenzie TT, Palacios BE, Hu J, Zhou H, Long J. Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas. Nat Commun. 2022;13:2724. https://doi.org/10.1038/s41467-022-30447-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cyra M, Schulte M, Berthold R, Heinst L, Jansen EP, Grünewald I, Elges S, Larsson O, Schliemann C, Steinestel K, Hafner S, Simmet T, Wardelmann E, Kailayangiri S, Rossig C, Isfort I, Trautmann M, Hartmann W. SS18-SSX drives CREB activation in synovial sarcoma. Cell Oncol (Dordr). 2022;45:399–413. https://doi.org/10.1007/s13402-022-00673-w.

Article  CAS  PubMed  Google Scholar 

de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, Meltzer PS, van Kessel AG. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res. 2006;66:9474–82. https://doi.org/10.1158/0008-5472.can-05-3726.

Article  PubMed  Google Scholar 

Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, Forscher C, Maki RG, Singer S. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246:105–13. https://doi.org/10.1097/01.sla.0000262787.88639.2b.

Article  PubMed  PubMed Central  Google Scholar 

El Beaino M, Araujo DM, Lazar AJ, Lin PP. Synovial sarcoma: advances in diagnosis and treatment identification of new biologic targets to improve multimodal therapy. Annals Surg Oncol. 2017;24:2145–54. https://doi.org/10.1245/s10434-017-5855-x.

Article  Google Scholar 

Forconi F, Ashton-Key M, Meakin N. bcl2 inhibition in refractory hairy-cell leukemia. N Engl J Med. 2023;388:2010–2. https://doi.org/10.1056/NEJMc2215613.

Article  PubMed  Google Scholar 

Gamero AM, Potla R, Wegrzyn J, Szelag M, Edling AE, Shimoda K, Link DC, Dulak J, Baker DP, Tanabe Y, Grayson JM, Larner AC. Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem. 2006;281:16238–44. https://doi.org/10.1074/jbc.M509516200.

Article  CAS  PubMed  Google Scholar 

Gazendam AM, Popovic S, Munir S, Parasu N, Wilson D, Ghert M. Synovial sarcoma: a clinical review. Curr Oncol. 2021;28:1909–20. https://doi.org/10.3390/curroncol28030177.

Article  PubMed  PubMed Central  Google Scholar 

Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11–9. https://doi.org/10.1016/j.cytogfr.2009.11.005.

Article  CAS  PubMed  Google Scholar 

Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18:812–22. https://doi.org/10.1016/s1470-2045(17)30334-0.

Article  CAS  PubMed  Google Scholar 

Hale R, Sandakly S, Shipley J, Walters Z. Epigenetic targets in synovial sarcoma: a mini-review. Front Oncol. 2019;9:1078. https://doi.org/10.3389/fonc.2019.01078.

Article  PubMed  PubMed Central  Google Scholar 

Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res : Official J Am Assoc Cancer Res. 2011;17:2619–27. https://doi.org/10.1158/1078-0432.CCR-10-1114.

Article  CAS  Google Scholar 

Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res : CR. 2024;43:23. https://doi.org/10.1186/s13046-024-02949-5.

Article  PubMed  PubMed Central  Google Scholar 

Ide H, Nakagawa T, Terado Y, Kamiyama Y, Muto S, Horie S. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem Biophys Res Commun. 2008;369:292–6. https://doi.org/10.1016/j.bbrc.2007.08.160.

Article  CAS  PubMed  Google Scholar 

Isfort I, Cyra M, Elges S, Kailayangiri S, Altvater B, Rossig C, Steinestel K, Grünewald I, Huss S, Eßeling E, Mikesch JH, Hafner S, Simmet T, Wozniak A, Schöffski P, Larsson O, Wardelmann E, Trautmann M, Hartmann W. SS18-SSX-dependent YAP/TAZ signaling in synovial sarcoma. Clin Cancer Resh : Official J Am Assoc Cancer Res. 2019;25:3718–31. https://doi.org/10.1158/1078-0432.ccr-17-3553.

Article  CAS  Google Scholar 

Jerby-Arnon L, Neftel C, Shore ME, Weisman HR, Mathewson ND, McBride MJ, Haas B, Izar B, Volorio A, Boulay G, Cironi L, Richman AR, Broye LC, Gurski JM, Luo CC, Mylvaganam R, Nguyen L, Mei S, Melms JC, Georgescu C, Cohen O, Buendia-Buendia JE, Segerstolpe A, Sud M, Cuoco MS, Labes D, Gritsch S, Zollinger DR, Ortogero N, Beechem JM, Petur Nielsen G, Chebib I, Nguyen-Ngoc T, Montemurro M, Cote GM, Choy E, Letovanec I, Cherix S, Wagle N, Sorger PK, Haynes AB, Mullen JT, Stamenkovic I, Rivera MN, Kadoch C, Wucherpfennig KW, Rozenblatt-Rosen O, Suvà ML, Riggi N, Regev A. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med. 2021;27:289–300. https://doi.org/10.1038/s41591-020-01212-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, Sharma S, Capecchi MR. SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene. 2013;32:2365–71, 75 e1 5. https://doi.org/10.1038/onc.2012.247.

Article  CAS  PubMed  Google Scholar 

Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153:71–85. https://doi.org/10.1016/j.cell.2013.02.036.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinasesignal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86:148–57. https://doi.org/10.1016/j.jaad.2021.06.869.

Article  CAS  PubMed  Google Scholar 

Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135–40.

CAS  PubMed  Google Scholar 

Leitner NR, Witalisz-Siepracka A, Strobl B, Muller M. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. Cytokine. 2017;89:209–18. https://doi.org/10.1016/j.cyto.2015.10.015.

Article  CAS  PubMed  Google Scholar 

Li H, Chen L, Li JJ, Zhou Q, Huang A, Liu WW, Wang K, Gao L, Qi ST, Lu YT. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway. J Hematol Oncol. 2018;11:70. https://doi.org/10.1186/s13045-018-0618-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Mulvihill TS, Li L, Barrott JJ, Nelson ML, Wagner L, Lock IC, Pozner A, Lambert SL, Ozenberger BB, Ward MB, Grossmann AH, Liu T, Banito A, Cairns BR, Jones KB. A role for SMARCB1 in synovial sarcomagenesis reveals that SS18-SSX induces canonical BAF destruction. Cancer Discov. 2021;11:2620–37. https://doi.org/10.1158/2159-8290.cd-20-1219.

Article